In AML, Immunotherapy Shows Promise to Expand Treatment Toolbox
Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).
Bristol Myers Squibb Vitalii Vodolazskyi Stock Acute Myeloid Leukemia Hematopoietic Stem Cell Tumor Microenvironment Immune Microenvironment
Source: ajmc.com